Financials and Corporate

Research collaboration and licensing agreement for new bispecific antibodies using Innate Pharma’s technology and Sanofi’s technology and tumor targets Innate Pharma eligible for up to €400m in...

This program, currently in preclinical development, aims at developing an anti-CD39 mAb; Targeting the adenosine immunosuppressive pathway has potential to promote anti-tumor immune responses across a...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces its tentative financial calendar for 2016, which is set as follows: February 18, 2016 : Publication of 2015...

Cash, cash equivalents and financial instruments amounting to €270 million ; US$5 million milestone payment received from Bristol-Myers Squibb for the initiation of a new Phase II trial in hemato...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) announced that it has received a US$5 million milestone payment from Bristol-Myers Squibb as part of the lirilumab licencing...